Elsevier acquires Windhover Information Inc., a Healthcare Business Intelligence Company
Acquisition extends Elsevier’s ability to gather global healthcare news and add to it in-depth analysis and commentary that will dramatically increase business value for customers
Philadelphia, PA March 10, 2008 – Elsevier, the world’s leading publisher of science, technical and health information, announced today that it has acquired Windhover Information Inc., a healthcare business intelligence company that provides analysis and commentary on healthcare business strategy, industry deal making, marketplace trends and medical start-ups.
The acquisition supports Elsevier’s e-Health strategy to improve patient healthcare and the business of health in the Pharma business intelligence market. It expands Elsevier’s offering of new products and services for Pharma industry professionals by combining innovative technology and industry-leading content to promote faster and better informed planning and management of product portfolios.
“Adding Windhover’s expert analysis of the pharmaceutical and medical device industries to our existing regulatory and general business news services and database expands both the depth and breadth of Elsevier’s customer offerings,” said Brian Nairn, CEO of Elsevier Health Sciences. “Windhover also provides an exciting platform for new products.”
Windhover produces authoritative journals such as IN VIVO and the RPM Report, the world’s most comprehensive database of healthcare industry transactions (Strategic Transactions Database), and a series of medical-device and biopharmaceutical partnering and strategy conferences. With Windhover, Elsevier will field a team of more than 100 journalists in bureaus covering healthcare developments across the globe.
The acquisition of Windhover is Elsevier’s latest in a series of highly synergistic investments in content, workflow tools and e-Health services. Windhover will operate within Elsevier’s Pharma Business Intelligence Unit, which includes F-D-C Reports, Inc. (including “The Pink Sheet” and “The Gray Sheet”) and Inteleos, a powerful drug development database.
“Elsevier is one of the few companies as dedicated to covering the business of healthcare as Windhover is,” said Roger Longman and David Cassack, Managing Partners and co-founders of Windhover. “We’re proud to align with The Pink Sheet and other F-D-C Reports products and provide growth opportunities for our staff.”
Terms of the acquisition are not being disclosed.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com